Work Package 5
Methods to improve the activation of immune cells
in the context of immunosuppression
Lead partner
Centre Hospitalier Universitaire Vaudois
Task leaders and participating partners
WP Objectives
To develop in vitro model using molecular pathway or specific targets found in WP2-3 for improving either dysfunctional or slow CMV-immune response in naïve patients for conventional T cells, T cells and NK cells
To develop mice model of CMV infection using molecular pathway found in WP2-3 for improving either dysfunctional or slow CMV-immune response for conventional T cells, T cells and NK cells,
To develop a clinical pilot “proof-of-concept" trial using a previously discovered immune signature at day 0 of CMV infection to propose a therapeutic intervention based on immune modulation of immunosuppressive therapy, for example the use of mTORi in patients with dysfunctional immune response to CMV.